Deac A-L, Burz CC, Bocșe HF et al (2020) A systematic review on the importance of genotyping and phenotyping in fluoropyrimidine treatment. Med Pharm Rep 93:223–230. https://doi.org/10.15386/mpr-1564

Article  PubMed  PubMed Central  Google Scholar 

Lunenburg CATC, Henricks LM, Guchelaar H-J et al (2016) Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer 54:40–48. https://doi.org/10.1016/j.ejca.2015.11.008

Article  PubMed  Google Scholar 

Sharma BB, Rai K, Blunt H et al (2021) Pathogenic DPYD Variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 26:1008–1016. https://doi.org/10.1002/onco.13967

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lunenburg CATC, van der Wouden CH, Nijenhuis M et al (2020) Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet 28:508–517. https://doi.org/10.1038/s41431-019-0540-0

Article  CAS  PubMed  Google Scholar 

Amstutz U, Henricks LM, Offer SM et al (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210–216. https://doi.org/10.1002/cpt.911

Article  CAS  PubMed  Google Scholar 

Offer SM, Lee AM, Mattison LK et al (2013) A DPYD variant (Y186C) in individuals of African ancestry associated with reduced DPD enzyme activity. Clin Pharmacol Ther 94:158–166. https://doi.org/10.1038/clpt.2013.69

Article  CAS  PubMed  Google Scholar 

Hertz DL (2023) Reply to H.S. Hochster. JCO 41:2120–2121. https://doi.org/10.1200/JCO.23.00038

Article  Google Scholar 

Haute Autorité de Santé (2018) Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine) - INAHTA Brief. https://www.has-sante.fr/jcms/c_2891090/en/screening-for-dihydropyrimidine-dehydrogenase-deficiency-to-decrease-the-risk-of-severe-toxicities-related-to-fluoropyrimidines-5-fluorouracil-or-capecitabine-inahta-brief. Accessed 7 Mar 2024

de With M, Knikman J, de Man FM et al (2022) Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study. Clin Pharmacol Ther 112:62–68. https://doi.org/10.1002/cpt.2608

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henricks LM, Lunenburg CATC, de Man FM et al (2018) DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 19:1459–1467. https://doi.org/10.1016/S1470-2045(18)30686-7

Article  CAS  PubMed  Google Scholar 

Brooks GA, Tapp S, Daly AT et al (2022) Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based adjuvant chemotherapy for colon cancer. Clin Colorectal Cancer 21:e189–e195. https://doi.org/10.1016/j.clcc.2022.05.001

Article  PubMed  PubMed Central  Google Scholar 

Morris SA, Moore DC, Musselwhite LW et al (2023) Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center. Am J Health Syst Pharm 80:1342–1349. https://doi.org/10.1093/ajhp/zxad117

Article  PubMed  Google Scholar 

Innocenti F, Mills SC, Sanoff H et al (2020) All you need to know about DPYD genetic testing for patients treated with fluorouracil and capecitabine: a practitioner-friendly guide. JCO Oncol Pract 16:793–798. https://doi.org/10.1200/OP.20.00553

Article  PubMed  PubMed Central  Google Scholar 

NHS England (2020) Clinical commissioning urgent policy statement: pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies. https://www.england.nhs.uk/wp-content/uploads/2020/11/1869-dpyd-policy-statement.pdf. Accessed 2 Mar 2024

Wörmann B, Bokemeyer C, Burmeister T et al (2020) Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper. Oncol Res Treat 43:628–636. https://doi.org/10.1159/000510258

Article  CAS  PubMed  Google Scholar 

de With M, Sadlon A, Cecchin E et al (2023) Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO Open 8(2):101197. https://doi.org/10.1016/j.esmoop.2023.101197

European Medicines Agency (2020) New testing and treatment recommendations for fluorouracil, capecitabine, tegafur and flucytosine. https://www.ema.europa.eu/en/documents/referral/fluorouracil-fluorouracil-related-substances-article-31-referral-new-testing-treatment_en.pdf. Accessed 2 Mar 2024

Halbisen AL, Lu CY (2023) Trends in availability of genetic tests in the United States, 2012–2022. J Pers Med 13:638. https://doi.org/10.3390/jpm13040638

Article  PubMed  PubMed Central  Google Scholar 

Anderson HD, Crooks KR, Kao DP, Aquilante CL (2020) The landscape of pharmacogenetic testing in a US managed care population. Genet Med 22:1247–1253. https://doi.org/10.1038/s41436-020-0788-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Empey PE, Stevenson JM, Tuteja S et al (2018) Multi-site investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy. Clin Pharmacol Ther 104:664–674. https://doi.org/10.1002/cpt.1006

Article  PubMed  Google Scholar 

Cavallari LH, Driest SLV, Prows CA et al (2019) Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet Med 21:2255–2263. https://doi.org/10.1038/s41436-019-0484-3

Article  PubMed  PubMed Central  Google Scholar 

Varughese LA, Lau-Min KS, Cambareri C et al (2020) DPYD and UGT1A1 pharmacogenetic testing in patients with gastrointestinal malignancies: an overview of the evidence and considerations for clinical implementation. Pharmacotherapy 40:1108–1129. https://doi.org/10.1002/phar.2463

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hertz DL, Smith DM, Scott SA et al (2023) Response to the FDA decision regarding DPYD testing prior to fluoropyrimidine chemotherapy. Clin Pharmacol Ther 114:768–779. https://doi.org/10.1002/cpt.2978

Article  CAS  PubMed  Google Scholar 

Benson et al. (2024) Colon cancer, version 1.2024, NCCN clinical practice guidelines in oncology. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 2 Mar 2024

Koo K, Pasternak AL, Henry NL et al (2022) Survey of US medical oncologists’ practices and beliefs regarding DPYD testing before fluoropyrimidine chemotherapy. JCO Oncol Pract 18:e958–e965. https://doi.org/10.1200/OP.21.00874

Article  PubMed  PubMed Central  Google Scholar 

Lau-Min KS, Varughese LA, Nelson MN et al (2022) Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation. BMC Cancer 22:47. https://doi.org/10.1186/s12885-022-09171-6

Article  PubMed  PubMed Central  Google Scholar 

Baker SD, Bates SE, Brooks GA et al (2023) DPYD testing: time to put patient safety first. JCO 41:2701–2705. https://doi.org/10.1200/JCO.22.02364

Article  Google Scholar 

Hertz DL (2022) Assessment of the clinical utility of pretreatment DPYD testing for patients receiving fluoropyrimidine chemotherapy. JCO 40:3882–3892. https://doi.org/10.1200/JCO.22.00037

Article  CAS  Google Scholar 

Knikman JE, Wilting TA, Lopez-Yurda M, et al (2023) Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy—a matched-pair analysis. J Clin Oncol 41(35):5411–5421. https://doi.org/10.1200/JCO.22.02780

Rompelman G, Espiritu J, Chen A et al (2023) Implementing a high-reliability, system-wide program for pre-emptive DPD deficiency testing for patients planned for a systemic fluoropyrimidine. JCO Oncol Pract 19:396–396. https://doi.org/10.1200/OP.2023.19.11_suppl.396

Article  Google Scholar 

Muldoon M, Beck M, Sebree N et al (2024) Real-world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community-based cancer center. Clin Transl Sci 17:e13704. https://doi.org/10.1111/cts.13704

Article  PubMed Central  Google Scholar 

Deenen MJ, Meulendijks D, Cats A et al (2016) Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. JCO 34:227–234. https://doi.org/10.1200/JCO.2015.63.1325

Article  CAS  Google Scholar 

Norris M, Dalton R, Alam B et al (2023) Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan. Front Genet 14:1249003. https://doi.org/10.3389/fgene.2023.1249003

Article  CAS